This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Psilocybin
Replicated clinical plasticity signal for treatment-resistant depression, end-of-life anxiety, and (smaller) substance-use disorder.
Aliases (7)
Overview
What is Psilocybin?
Replicated clinical plasticity signal for treatment-resistant depression, end-of-life anxiety, and (smaller) substance-use disorder. Macrodose ("trip") therapy with supported setting is where the evidence sits — microdose data is largely null in placebo-controlled trials. Not a fit for a healthy 20yo with no indication. First-break psychosis in vulnerable users is the dominant permanent-harm risk.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Acute: nausea, vomiting (especially raw mushrooms), transient anxiety, transient blood-pressure rise, headache next day.
- Psychological: challenging experiences ("bad trips") — frequency ~20-30% in clinical settings, much higher unsupported. Usually integratable; occasionally precipitates extended distress.
- Rare-serious-permanent: HPPD, first-break psychosis in vulnerable users, persistent affective dysregulation. All rare but documented and not reliably reversible.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.